MicroRNA library screening identifies growth-suppressive microRNAs that regulate genes involved in cell cycle progression and apoptosis

Experimental Cell Research

Volumn 339, Issue 2, 2015, Pages 320-332

  Choi, Young Chul ^a   Yoon, Sena ^a   Byun, Yuree ^a   Lee, Gangtae ^a   Kee, Honghwan ^a   Jeong, Yongsu ^a   Yoon, Jaeseung ^a   Baek, Kwanghee ^a  

^a Kyung Hee University   (South Korea)

Author keywords

Apoptosis; Growth inhibition; MicroRNA; MiR 608; Screening

Indexed keywords

B CELL LYMPHOMA 2 LIKE 1 PROTEIN; BACULOVIRAL IAP REPEAT CONTAINING 2; BACULOVIRAL IAP REPEAT CONTAINING 3; BACULOVIRAL IAP REPEAT CONTAINING 5; BCL 2 INTERACTING KILLER PROTEIN; CAMPTOTHECIN; CASPASE 3; CASPASE 7; CASPASE 8; CYCLIN D1; CYCLIN D2; CYCLIN D3; CYCLIN E; CYTOCHROME B5 REDUCTASE 3; MICRORNA; MICRORNA 28; MICRORNA 323; MICRORNA 510; MICRORNA 552; MICRORNA 608; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PHOSPHOINOSITIDE 3 KINASE REGULATORY SUBUNIT 2; POLO LIKE KINASE 1; PROTEIN; PROTEIN BCL 2; PROTEIN KINASE B; TRANSCRIPTION FACTOR E2F2; TRANSCRIPTION FACTOR E2F3; TRANSCRIPTION FACTOR SP1; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

A549 CELL LINE; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME PHOSPHORYLATION; FEMALE; FLOW CYTOMETRY; G1 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; GENE LIBRARY; GROWTH INHIBITION; HELA CELL LINE; HUMAN; HUMAN CELL; MALE; MCF 7 CELL LINE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROTEIN CLEAVAGE; ANIMAL; BAGG ALBINO MOUSE; CELL CYCLE; CELL PROLIFERATION; DRUG SCREENING; EXPERIMENTAL NEOPLASM; GENETICS; METABOLISM; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; GENE LIBRARY; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; MICRORNAS; NEOPLASMS, EXPERIMENTAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84951138992     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2015.10.012     Document Type: Article

References (68)

1. [1] Bartel, D.P., MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116 (2004), 281–297.
2. [2] He, L., Hannon, G.J., MicroRNAs with a big role in gene regulation. Nat. Rev. Genet. 5 (2004), 522–531.
3. [3] Shenouda, S.K., Alahari, S.K., MicroRNA function in cancer: oncogene or a tumor suppressor?. Cancer Metastas. – Rev. 28 (2009), 369–378.
4. [4] Hoshino, I., Matsubara, H., MicroRNAs in cancer diagnosis and therapy: from bench to bedside. Surg. Today 43 (2013), 467–478.
5. [5] He, L., He, X., Lim, L.P., de Stanchina, E., Xuan, Z., Liang, Y., Xue, W., Zender, L., Magnus, J., Ridzon, D., Jackson, A.L., Linsley, P.S., Chen, C., Lowe, S.W., Cleary, M.A., Hannon, G.J., A microRNA component of the p53 tumour suppressor network. Nature 447 (2007), 1130–1134.
6. [6] Hermeking, H., p53 enters the microRNA world. Cancer Cell 12 (2007), 414–418.
7. [7] Hermeking, H., The miR-34 family in cancer and apoptosis. Cell.Death Differ. 17 (2010), 193–199.
8. [8] Bader, A.G., miR-34-a microRNA replacement therapy is headed to the clinic. Front. Genet., 3, 2012, 120.
9. [9] Wiggins, J.F., Ruffino, L., Kelnar, K., Omotola, M., Patrawala, L., Brown, D., Bader, A.G., Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. Cancer Res. 70 (2010), 5923–5930.
10. [10] Trang, P., Wiggins, J.F., Daige, C.L., Cho, C., Omotola, M., Brown, D., Weidhaas, J.B., Bader, A.G., Slack, F.J., Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. Mol. Ther. 19 (2011), 1116–1122.
11. [11] Di Martino, M.T., Campani, V., Misso, G., Gallo Cantafio, M.E., Gullà, A., Foresta, U., Guzzi, P.H., Castellano, M., Grimaldi, A., Gigantino, V., Franco, R., Lusa, S., Cannataro, M., Tagliaferri, P., De Rosa, G., Tassone, P., Caraglia, M., In vivo activity of miR-34a mimics delivered by stable nucleic acid lipid particles (SNALPs) against multiple myeloma. PLoS One, 9, 2014, e90005.
12. [12] Agostini, M., Knight, R.A., miR-34: from bench to bedside. Oncotarget 5 (2014), 872–881.
13. [13] Lim, L.P., Lau, N.C., Garrett-Engele, P., Grimson, A., Schelter, J.M., Castle, J., Bartel, D.P., Linsley, P.S., Johnson, J.M., Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature 433 (2005), 769–773.
14. [14] Baek, D., Villén, J., Shin, C., Camargo, F.D., Gygi, S.P., Bartel, D.P., The impact of microRNAs on protein output. Nature 455 (2008), 64–71.
15. [15] Selbach, M., Schwanhäusser, B., Thierfelder, N., Fang, Z., Khanin, R., Rajewsky, N., Widespread changes in protein synthesis induced by microRNAs. Nature 455 (2008), 58–63.
16. [16] Cheng, A.M., Byrom, M.W., Shelton, J., Ford, L.P., Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis. Nucleic Acids Res. 33 (2005), 1290–1297.
17. [17] Poell, J.B., van Haastert, R.J., de Gunst, T., Schultz, I.J., Gommans, W.M., Verheul, M., Cerisoli, F., van Noort, P.I., Prevost, G.P., Schaapveld, R.Q., Cuppen, E., A functional screen identifies specific microRNAs capable of inhibiting human melanoma cell viability. PLoS One, 7, 2012, e43569.
18. [18] Christensen, L.L., Holm, A., Rantala, J., Kallioniemi, O., Rasmussen, M.H., Ostenfeld, M.S., Dagnaes-Hansen, F., Øster, B., Schepeler, T., Tobiasen, H., Thorsen, K., Sieber, O.M., Gibbs, P., Lamy, P., Hansen, T.F., Jakobsen, A., Riising, E.M., Helin, K., Lubinski, J., Hagemann-Madsen, R., Laurberg, S., Ørntoft, T.F., Andersen, C.L., Functional screening identifies miRNAs influencing apoptosis and proliferation in colorectal cancer. PLoS One, 9, 2014, e96767.
19. [19] Nakano, H., Miyazawa, T., Kinoshita, K., Yamada, Y., Yoshida, T., Functional screening identifies a microRNA, miR-491 that induces apoptosis by targeting Bcl-X(L) in colorectal cancer cells. Int. J. Cancer 127 (2010), 1072–1080.
20. [20] Zhang, H., Hao, Y., Yang, J., Zhou, Y., Li, J., Yin, S., Sun, C., Ma, M., Huang, Y., Xi, J.J., Genome-wide functional screening of miR-23b as a pleiotropic modulator suppressing cancer metastasis. Nat. Commun., 2, 2011, 554.
21. [21] Zhao, Z., Ma, X., Hsiao, T.H., Lin, G., Kosti, A., Yu, X., Suresh, U., Chen, Y., Tomlinson, G.E., Pertsemlidis, A., Du, L., A high-content morphological screen identifies novel microRNAs that regulate neuroblastoma cell differentiation. Oncotarget 5 (2014), 2499–2512.
22. [22] Frankel, L.B., Wen, J., Lees, M., Høyer-Hansen, M., Farkas, T., Krogh, A., Jäättelä, M., Lund, A.H., MicroRNA-101 is a potent inhibitor of autophagy. EMBO J. 30 (2011), 4628–4641.
23. [23] Kim, S., Lee, U.J., Kim, M.N., Lee, E.J., Kim, J.Y., Lee, M.Y., Choung, S., Kim, Y.J., Choi, Y.C., MicroRNA miR-199a* regulates the MET proto-oncogene and the downstream extracellular signal-regulated kinase 2 (ERK2). J. Biol. Chem. 283 (2008), 18158–18166.
24. [24] Wang, W., Peng, B., Wang, D., Ma, X., Jiang, D., Zhao, J., Yu, L., Human tumor microRNA signatures derived from large-scale oligonucleotide microarray datasets. Int. J. Cancer 129 (2011), 1624–1634.
25. [25] Liu, Q., Fu, H., Sun, F., Zhang, H., Tie, Y., Zhu, J., Xing, R., Sun, Z., Zheng, X., miR-16 family induces cell cycle arrest by regulating multiple cell cycle genes. Nucleic Acids Res. 36 (2008), 5391–5404.
26. [26] Yoon, S., Choi, Y.C., Lee, S., Jeong, Y., Yoon, J., Baek, K., Induction of growth arrest by miR-542-3p that targets survivin. FEBS Lett. 584 (2010), 4048–4052.
27. [27] Choung, S., Kim, Y.J., Kim, S., Park, H.O., Choi, Y.C., Chemical modification of siRNAs to improve serum stability without loss of efficacy. Biochem. Biophys. Res. Commun. 342 (2006), 919–927.
28. [28] Susin, S.A., Lorenzo, H.K., Zamzami, N., Marzo, I., Snow, B.E., Brothers, G.M., Mangion, J., Jacotot, E., Costantini, P., Loeffler, M., Larochette, N., Goodlett, D.R., Aebersold, R., Siderovski, D.P., Penninger, J.M., Kroemer, G., Molecular characterization of mitochondrial apoptosis-inducing factor. Nature 397 (1999), 441–446.
29. [29] Daugas, E., Susin, S.A., Zamzami, N., Ferri, K.F., Irinopoulou, T., Larochette, N., Prévost, M.C., Leber, B., Andrews, D., Penninger, J., Kroemer, G., Mitochondrio-nuclear translocation of AIF in apoptosis and necrosis. FASEB J. 14 (2000), 729–739.
30. [30] Miramar, M.D., Costantini, P., Ravagnan, L., Saraiva, L.M., Haouzi, D., Brothers, G., Penninger, J.M., Peleato, M.L., Kroemer, G., Susin, S.A., NADH oxidase activity of mitochondrial apoptosis-inducing factor. J. Biol. Chem. 276 (2001), 16391–16398.
31. [31] Youle, R.J., Strasser, A., The BCL-2 protein family: opposing activities that mediate cell death. Nat. Rev. Mol. Cell. Biol. 9 (2008), 47–59.
32. [32] Czabotar, P.E., Lessene, G., Strasser, A., Adams, J.M., Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat. Rev. Mol. Cell. Biol. 15 (2014), 49–63.
33. [33] Gozuacik, D., Kimchi, A., Autophagy as a cell death and tumor suppressor mechanism. Oncogene 23 (2004), 2891–2906.
34. [34] Lee, M.H., Yang, H.Y., Regulators of G1 cyclin-dependent kinases and cancers. Cancer Metastas. – Rev. 22 (2003), 435–449.
35. [35] Dyson, N., The regulation of E2F by pRB-family proteins. Genes Dev. 12 (1998), 2245–2262.
36. [36] Chang, F., Lee, J.T., Navolanic, P.M., Steelman, L.S., Shelton, J.G., Blalock, W.L., Franklin, R.A., McCubrey, J.A., Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. Leukemia 17 (2003), 590–603.
37. [37] Stephens, L., Anderson, K., Stokoe, D., Erdjument-Bromage, H., Painter, G.F., Holmes, A.B., Gaffney, P.R., Reese, C.B., McCormick, F., Tempst, P., Coadwell, J., Hawkins, P.T., Protein kinase B kinases that mediate phosphatidylinositol 3,4,5-trisphosphate-dependent activation of protein kinase B. Science 279 (1998), 710–714.
38. [38] Sarbassov, D.D., Guertin, D.A., Ali, S.M., Sabatini, D.M., Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307 (2005), 1098–1101.
39. [39] Huang, P.H., Xu, A.M., White, F.M., Oncogenic EGFR signaling networks in glioma. Sci. Signal., 2, 2009, re6.
40. [40] Safe, S., Abdelrahim, M., Sp transcription factor family and its role in cancer. Eur. J. Cancer 41 (2005), 2438–2448.
41. [41] Othman, N., In, L.L., Harikrishna, J.A., Hasima, N., Bcl-xL silencing induces alterations in hsa-miR-608 expression and subsequent cell death in A549 and SK-LU1 human lung adenocarcinoma cells. PLoS One, 8, 2013, e81735.
42. [42] Zhang, Y., Schiff, D., Park, D., Abounader, R., MicroRNA-608 and microRNA-34a regulate chordoma malignancy by targeting EGFR, Bcl-xL and MET. PLoS One, 9, 2014, e91546.
43. [43] Boyd, J.M., Gallo, G.J., Elangovan, B., Houghton, A.B., Malstrom, S., Avery, B.J., Ebb, R.G., Subramanian, T., Chittenden, T., Lutz, R.J., Bik, a novel death-inducing protein shares a distinct sequence motif with Bcl-2 family proteins and interacts with viral and cellular survival-promoting proteins. Oncogene 11 (1995), 1921–1928.
44. [44] Sturm, I., Stephan, C., Gillissen, B., Siebert, R., Janz, M., Radetzki, S., Jung, K., Loening, S., Dörken, B., Daniel, P.T., Loss of the tissue-specific proapoptotic BH3-only protein Nbk/Bik is a unifying feature of renal cell carcinoma. Cell Death Differ. 13 (2006), 619–627.
45. [45] Dai, Z., Liu, S., Marcucci, G., Sadee, W., 5-Aza-2'-deoxycytidine and depsipeptide synergistically induce expression of BIK (BCL2-interacting killer). Biochem. Biophys. Res. Commun. 351 (2006), 455–461.
46. [46] Zhu, H., Zhang, L., Dong, F., Guo, W., Wu, S., Teraishi, F., Davis, J.J., Chiao, P.J., Fang, B., Bik/NBK accumulation correlates with apoptosis-induction by bortezomib (PS-341, Velcade) and other proteasome inhibitors. Oncogene 24 (2005), 4993–4999.
47. [47] Li, C., Li, R., Grandis, J.R., Johnson, D.E., Bortezomib induces apoptosis via Bim and Bik up-regulation and synergizes with cisplatin in the killing of head and neck squamous cell carcinoma cells. Mol. Cancer Ther. 7 (2008), 1647–1655.
48. [48] Hur, J., Bell, D.W., Dean, K.L., Coser, K.R., Hilario, P.C., Okimoto, R.A., Tobey, E.M., Smith, S.L., Isselbacher, K.J., Shioda, T., Regulation of expression of BIK proapoptotic protein in human breast cancer cells: p53-dependent induction of BIK mRNA by fulvestrant and proteasomal degradation of BIK protein. Cancer Res. 66 (2006), 10153–10161.
49. [49] Real, P.J., Sanz, C., Gutierrez, O., Pipaon, C., Zubiaga, A.M., Fernandez-Luna, J.L., Transcriptional activation of the proapoptotic bik gene by E2F proteins in cancer cells. FEBS Lett. 580 (2006), 5905–5909.
50. [50] Hur, J., Chesnes, J., Coser, K.R., Lee, R.S., Geck, P., Isselbacher, K.J., Shioda, T., The Bik BH3-only protein is induced in estrogen-starved and antiestrogen-exposed breast cancer cells and provokes apoptosis. Proc. Natl. Acad. Sci. U.S A. 101 (2004), 2351–2356.
51. [51] Mebratu, Y.A., Dickey, B.F., Evans, C., Tesfaigzi, Y., The BH3-only protein Bik/Blk/Nbk inhibits nuclear translocation of activated ERK1/2 to mediate IFNgamma-induced cell death. J. Cell. Biol. 183 (2008), 429–439.
52. [52] Spender, L.C., O'Brien, D.I., Simpson, D., Dutt, D., Gregory, C.D., Allday, M.J., Clark, L.J., Inman, G.J., TGF-beta induces apoptosis in human B cells by transcriptional regulation of BIK and BCL-XL. Cell Death Differ. 16 (2009), 593–602.
53. [53] Elangovan, B., Chinnadurai, G., Functional dissection of the pro-apoptotic protein Bik. Heterodimerization with anti-apoptosis proteins is insufficient for induction of cell death. J. Biol. Chem. 272 (1997), 24494–24498.
54. [54] Yang, E., Zha, J., Jockel, J., Boise, L.H., Thompson, C.B., Korsmeyer, S.J., Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death. Cell 80 (1995), 285–291.
55. [55] Zha, J., Harada, H., Osipov, K., Jockel, J., Waksman, G., Korsmeyer, S.J., BH3 domain of BAD is required for heterodimerization with BCL-XL and pro-apoptotic activity. J. Biol. Chem. 272 (1997), 24101–24104.
56. [56] Kelekar, A., Chang, B.S., Harlan, J.E., Fesik, S.W., Thompson, C.B., Bad is a BH3 domain-containing protein that forms an inactivating dimer with Bcl-XL. Mol. Cell. Biol. 17 (1997), 7040–7046.
57. [57] Datta, S.R., Dudek, H., Tao, X., Masters, S., Fu, H., Gotoh, Y., Greenberg, M.E., Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91 (1997), 231–241.
58. [58] del Peso, L., González-García, M., Page, C., Herrera, R., Nuñez, G., Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science 278 (1997), 687–689.
59. [59] Scheid, M.P., Schubert, K.M., Duronio, V., Regulation of bad phosphorylation and association with Bcl-x(L) by the MAPK/Erk kinase. J. Biol. Chem. 274 (1999), 31108–31113.
60. [60] Harada, H., Andersen, J.S., Mann, M., Terada, N., Korsmeyer, S.J., p70S6 kinase signals cell survival as well as growth, inactivating the pro-apoptotic molecule BAD. Proc. Natl. Acad. Sci. U.S A. 98 (2001), 9666–9670.
61. [61] Virdee, K., Parone, P.A., Tolkovsky, A.M., Phosphorylation of the pro-apoptotic protein BAD on serine 155, a novel site, contributes to cell survival. Curr. Biol., 10, 2000, R883.
62. [62] Fulda, S., Debatin, K.M., Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 25 (2006), 4798–4811.
63. [63] Degterev, A., Boyce, M., Yuan, J., A decade of caspases. Oncogene 22 (2003), 8543–8567.
64. [64] Levine, B., Yuan, J., Autophagy in cell death: an innocent convict?. J. Clin. Invest. 115 (2005), 2679–2688.
65. [65] Galluzzi, L., Kroemer, G., Necroptosis: a specialized pathway of programmed necrosis. Cell 135 (2008), 1161–1163.
66. [66] Sperandio, S., de Belle, I., Bredesen, D.E., An alternative, nonapoptotic form of programmed cell death. Proc. Natl. Acad. Sci. U.S A. 97 (2000), 14376–14381.
67. [67] Wang, Y., Dawson, V.L., Dawson, T.M., Poly(ADP-ribose) signals to mitochondrial AIF: a key event in parthanatos. Exp. Neurol. 218 (2009), 193–202.
68. [68] Castedo, M., Perfettini, J.L., Roumier, T., Andreau, K., Medema, R., Kroemer, G., Cell death by mitotic catastrophe: a molecular definition. Oncogene 23 (2004), 2825–2837.